iLux Treatment for Meibomian Gland Dysfunction (MGD)
The iLux and Mechanical Meibomian Gland Expression for the Treatment of Moderate and Severe Meibomian Gland Dysfunction.
Summary:
Purpose: To compare the safety and efficacy of eyelid treatment with the ILux®-MGD Treatment System in one session versus five sessions of mechanical meibomian gland expression (MMGE) in patients with moderate to severe meibomian gland dysfunction (MGD).
Methods: Prospective, randomized, open-label, controlled clinical trial comparing one session of the ILux® MGD Treatment System versus five sessions of MMGE in both eyes of 130 patients aged ≥18 years with OSDI scores ≥13, total MGS of 15 in the lower lid of each eye and NI-TBUT <10 s, who were randomized 1:1 to ILux® or MMGE.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Meibomian glands (MG) are responsible for the secretion of lipids (meibum) into the ocular surface and have a protective role for tear film against evaporation1-4; therefore, Meibomian Gland Dysfunction (MGD) is associated with evaporative dry eye (EDE). Hyperkeratinization and hyperviscosity occur in dysfunctions with low MG expressibility, low meibum quality and eyelid margin inflammation. Finally, atrophy and dropout of MGs in some cases could appear MGD is a prevalent dry eye disorder (DED) with an estimated prevalence range between 3.5% and 70%1,10-13, it constitutes the primary underlying pathology within the EDE subtype. On top of this, MGD is chronic and progressive, so it is imperative to identify clinical approaches that can effectively target this underlying condition.
Treatment of MGD often involves artificial lubricants, topical lipid supplements, lid hygiene, warm compression or heat application, supplement omega-3, topical and systemic antibiotics against Demodex mite infestation, and steroids.
Mechanical management involves debridement-scaling of the line of Marx and lowers lid margin21, and other methods for mechanical manual expression in alignment with the concept that optimal treatment of MGD requires the employment of some forms of evacuating MGs contents.
Eyelid thermal pulsation devices combine the application of heat at the appropriate temperature to the palpebral surface with simultaneous compression of the glands to evacuate their contents, and have been shown to improve signs and symptoms over 12 months in cases of severe meibomian obstruction.
More recently, the ILux® MGD Treatment System (Alcon, FortWorth, TX, USA) is an eyelid thermal pulsation system that includes a single-use patient interface device and a portable battery-powered instrument that simultaneously applies localized heat and compression to treat MGD and showed significant improvements in MG function between one and four weeks.
Prior to the introduction of vectored thermal pulsation therapies, the limitations of the practice for mechanical meibomian gland expression (MMGE) were pain caused by forced evacuation of the gland, difficulty with adequate sustained temperature at the eyelid at therapeutic levels ≥ 40°C28, and duration of effect demonstrated in only one month. In the patients five sessions per year of this combined treatment for moderate and severe DGM was performet.
The aim of this study is to compare the safety and efficacy of one-session eyelid treatment with the ILux® DGM treatment device versus five sessions in MMGE consultation in patients with moderate and severe DGM in a follow-up.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Valle Del Cauca
-
Cali, Valle Del Cauca, Colombia, 760036
- Clínica de Oftalmología de Cali S.A
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age at least 18 years
- A history of self-reported dry eye symptoms for two months prior to study enrollment,
- Diagnosis of MGD Low delivery type, with mechanism obstructive and non- cicatricial with scores as follows: Ocular Surface Disease Index (OSDI) questionnaire ≥ 13, Non-Invasive Tear break-up time (NIBUT) lower than 10 seconds (The Sirius anterior segment analyzer (CSO, Florence, Italy).
- Meibomian gland scores (MGS) lower than 15.
Exclusion Criteria:
- A history of ocular surgery
- Allergic conjunctivitis
- Seborrheic dermatitis
- Rosacea
- Psoriasis
- Punctal plugs or previous punctal cautery
- Anterior or demodex blepharitis
- Cicatricial lid margin disease
- Ocular injury or trauma
- Chemical burns
- Limbal stem cell deficiency
- Active ocular infection or non-dry eye inflammation
- Aqueous-deficient dry eye
- Irregular cornea
- Lid abnormalities and systemic disease conditions
- Medications that cause dry eye.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: iLUX Treatment System
The eyelid tissue is warmed by light energy produced by LEDs in the Instrument and transmitted through the precise Outer Pad.
The Inner Pad and Eye Shield block light transmission directly into the eye during a treatment temperature sensor and measure the inner and outer eyelid temperatures to maintain a meibum melt temperature of 38-42°C.
|
Local heat using an electrical warming mask for 5 minutes.
Other Names:
|
|
Active Comparator: Mechanical Meibomian Gland Expression
|
Local heat using an electrical warming mask for 5 minutes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effectiveness defined as changes from baseline to 1, 3, 6, 9 and 12 months in Non Invasive Tear break-up time (NI-TBUT) in seconds.
Time Frame: 1 year
|
NIBUT measured by SIRIUS device in seconds.
|
1 year
|
|
Effectiveness defined as changes from baseline to 1, 3, 6, 9 and 12 months in Meibomian gland scores (MGS).
Time Frame: 1 year
|
Using a Meibomian Gland Evaluator (MGE 1000) to grade a total score for 15 meibomian glands in the lower eyelid evaluated in 3 areas: nasal (5 glands), medial (5 glands), and temporal (5 glands) expressed & graded from 0 to 3 (0 = no secretion, 1 = inspissated, 2 = cloudy, 3 = clear liquid).
|
1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020001-00
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.